A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

June 18, 2024

Study Completion Date

June 18, 2024

Conditions
Triple Negative Breast CancerEndometrial CancerSolid Tumor, Unspecified, AdultColorectal Cancer
Interventions
DRUG

Fruquintinib

Oral VEGFR inhibitor

DRUG

Tislelizumab

PD-1 inhibitor

Trial Locations (16)

28806

Messino Cancer Center, Asheville

32308

Florida Cancer Specialists Panhandle, Tallahassee

33401

Florida Cancer Specialists - East (FCS East), West Palm Beach

33709

Florida Cancer Center North, St. Petersburg

33980

Florida Cancer Specialists - FCS South, Port Charlotte

37203

Tennesse Oncology, Nashville

37232

Vanderbilt Ingram Cancer Center, Nashville

37404

Tennessee Oncology-Chattanooga, Chattanooga

70809

HOC AON Baton Rouge / Sarah Cannon, Baton Rouge

72762

Highlands Oncology, Springdale

73104

Oklahoma University Stephenson Cancer Center, Oklahoma City

77030

The University of Texas MD Anderson Cancer Center, Houston

80045

University of Colorado, Aurora

85054

Mayo Clinic Arizona, Phoenix

90211

Beverly Hills Cancer Center, Beverly Hills

02905

Women and Infants Hospital of Rhode Island, Providence

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

BeiGene

INDUSTRY

lead

Hutchmed

INDUSTRY